Gyre Therapeutics, Inc. GYRE Contiva — Revenue (Gross)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s contiva — revenue (gross).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s contiva — revenue (gross)?
- Gyre Therapeutics, Inc. (GYRE) reported contiva — revenue (gross) of $849 in Q1 2026.
- How has Gyre Therapeutics, Inc.'s contiva — revenue (gross) changed year-over-year?
- Gyre Therapeutics, Inc.'s contiva — revenue (gross) increased by 204.3% year-over-year, from $279 to $849.
- What does contiva — revenue (gross) mean?
- This metric represents the total gross revenue recognized from contracts with customers for the Contiva product line, inclusive of any assessed taxes. It serves as a primary indicator of the market adoption and commercial performance of this specific segment. Tracking this figure helps investors assess the revenue contribution and growth trajectory of the Contiva business unit relative to the company's overall portfolio.